Last reviewed · How we verify
Retigabine IR
Retigabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability.
Retigabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability. Used for Partial-onset seizures (adjunctive therapy), Epilepsy.
At a glance
| Generic name | Retigabine IR |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Potassium channel opener; anticonvulsant |
| Target | Kv7 (KCNQ) voltage-gated potassium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Retigabine is a potassium channel opener that stabilizes the inactive state of voltage-gated potassium channels (particularly Kv7 channels), leading to hyperpolarization of neuronal membranes and decreased action potential firing. This mechanism reduces abnormal electrical activity in the brain, making it effective as an anticonvulsant. By suppressing neuronal hyperexcitability, it prevents seizure propagation.
Approved indications
- Partial-onset seizures (adjunctive therapy)
- Epilepsy
Common side effects
- Dizziness
- Somnolence
- Confusion
- Vertigo
- Tremor
- Blue discoloration of skin/sclera
- Diplopia
- Urinary retention
Key clinical trials
- Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (PHASE4)
- Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (PHASE3)
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (PHASE3)
- Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (PHASE3)
- An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation. (PHASE1)
- Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Retigabine IR CI brief — competitive landscape report
- Retigabine IR updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI